News

The latest Ebola outbreak in western Democratic Republic of Congo has led to at least 100 cases as of Friday, according to WHO.

Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.

School administrators, nurses and teachers are trying to develop plans to bring students back for critical in-school learning while keeping staff and immune-suppressed students safe.

The vaccine candidate, BNT162b2, was well-tolerated and phase 3 enrollment is more than one-third complete.

HIV-positive to HIV-positive kidney and liver transplantation showed no evidence of HIV superinfection, a new study in The Lancet HIV found.

Rodney E. Rohde, a clinical laboratory specialist at Texas State University, goes into the competing priorities of college and K-12 school reopening.

Scientists are willing to speak out and have collegial debates – but medical institutions and media have to catch up: fringe voices are often the only ones platformed to discuss important scientific nuances or debates.

In unexposed blood samples, investigators discovered memory helper T cells that recognize cold coronaviruses also recognized SARS-CoV-2, and may help people fight off the virus.

Postmarketing vaccine experience with vaccines suggests the candidates approved by the FDA for COVID-19 will be safe and effective

Robert H. Christenson, PhD, describes the threat of AMR and the role of relevant diagnostics in clinical settings.

Pediatricians agree schools are critical for child development and mental health. But their safety from the pandemic cannot be comprised for it.

The US FDA was said to be considering an emergency authorization for COVID-19 plasma just last week. For now, the authorization is on hold.

Join us tomorrow for an informative discussion on CDC guidance and insights from medical experts on navigating a way back to in-school learning.

Symptomatic case fatality ratio and infection fatality ratio provide a more accurate picture of pandemic, they say.

Citing the rise of the anti-vaccine movement, Peter Hotez, MD, PhD, explains the role scientists can play in building trust and literacy by engaging the public.

Rodney E. Rohde, PhD, a clinical laboratory scientist, helps break down how carefully EUA releases need to be read in order for the public and for scientists from other fields to parse them for useful information.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

ViiV Healthcare’s recent FDA approval of expanding a combination antiretroviral comes on the heels of the important data from the TANGO study.

Study authors collected more than 7000 S. pneumoniae isolates between 2009 and 2017.

The ideal time to act on COVID-19 was in January, says public health expert Raj Bhopal.

The US CDC has been engaged in a back and forth with media for several days after reductionist reporting on immunity related to COVID-19 suggested categorical proof of antibody based immunity to reinfection.

In a small study, preliminary analysis shows patients given this treatment early in hospitalization showed improvement and reduced mortality rates.

The human IgG1 monoclonal antibody TY014 showed promise as a possible prophylaxis or post-exposure treatment for yellow fever in a Phase 1 trial in Singapore.

July ended with nearly 100,000 new cases among children in the US. What does that mean for public and school reopenings?

SalivaDirect is unique in that it does not require a particular type of swab or collection device; any sterile container is suitable for saliva collection with the test.

The FDA regularly posts updates on recalls, outbreak investigations, and related regulatory activities. Weekly, we identify which of those announcements might be most clinically relevant.

Armand Balboni, MD, PhD, discusses progress toward FDA authorization and/or approval of favipiravir for COVID-19 as a prophylactic measure.